Atlas/ACR details 6,312,454 SLVM shares; board changes noted
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13D/A
Atlas/ACR-affiliated holders filed Amendment No. 3 to their Schedule 13D on Sylvamo (SLVM). The group reports beneficial ownership of 6,312,454 shares of common stock, or 15.64%, based on 40,372,555 shares outstanding as of August 1, 2025.
On November 5, 2025, to terminate the “Cooperation Period” under a Cooperation Agreement, the reporting persons delivered Director Resignation Notices designating that Karl Meyers and Mark Wilde resign from the board and waived their right to recommend substitutes. The filing states the group may consider various strategic actions and will continue to review its investment.
The filing also discloses a financing item: ACR Group Paper Holdings JR LP has borrowed approximately $254.9 million under a margin loan facility. Each reporting person disclaims beneficial ownership except for shares held directly.
Positive
- None.
Negative
- None.
Insights
Stake disclosed at 15.64%; cooperation period actions taken.
Atlas/ACR reports 6,312,454 shares (15.64%) of Sylvamo, anchoring the figure to 40,372,555 shares outstanding as of August 1, 2025. The amendment details steps taken on November 5, 2025 to end the Cooperation Agreement’s “Cooperation Period.”
They delivered Director Resignation Notices designating Karl Meyers and Mark Wilde resign and waived the right to propose substitutes. The schedule also preserves flexibility for future actions across transactions, governance, capital structure, or sales/purchases of securities.
The filing notes a margin loan of about $254.9 million at ACR Group Paper Holdings JR LP. Actual impact depends on future decisions and any subsequent company or holder disclosures.
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)
|
Sylvamo Corporation (Name of Issuer) |
Common Stock, par value $1.00 per share (Title of Class of Securities) |
871332102 (CUSIP Number) |
Michael O'Donnell, Esq. Atlas FRM LLC, 100 Northfield Street Greenwich, CT, 06830 (203) 622-9138 Steven A. Seidman, Esq. Willkie Farr & Gallagher LLP, 787 Seventh Avenue New York, NY, 10019-6099 (212) 728-8000 Mark A. Cognetti, Esq. Willkie Farr & Gallagher LLP, 787 Seventh Avenue New York, NY, 10019-6099 (212) 728-8000 Laura H. Acker, Esq. Willkie Farr & Gallagher LLP, 787 Seventh Avenue New York, NY, 10019-6099 (212) 728-8000 Brittany A. Klinger, Esq. Willkie Farr & Gallagher LLP, 787 Seventh Avenue New York, NY, 10019-6099 (212) 728-8000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
11/05/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
ACR Group Paper Holdings JR LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
ACR Group Paper Holdings JR GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
ACR Group Paper Holdings LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
Atlas Capital GP IV LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
Atlas Capital Resources GP IV LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
Atlas GP Global Holdings LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
Andrew M. Bursky | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| CUSIP No. | 871332102 |
| 1 |
Name of reporting person
Timothy J. Fazio | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,312,454.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
15.64 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Row 8, 10 and 11. The reporting person expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer other than the Common Stock of the Issuer owned directly by such reporting person.
Row 13. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $1.00 per share | |
| (b) | Name of Issuer:
Sylvamo Corporation | |
| (c) | Address of Issuer's Principal Executive Offices:
6077 Primacy Parkway, Memphis,
TENNESSEE
, 38119. | |
Item 1 Comment:
This Amendment No. 3 ("Amendment No. 3") amends the Schedule 13D filed on April 25, 2022 (the "Original Schedule 13D" and, as amended, the "Schedule 13D"), as amended by Amendment No. 1 filed on February 15, 2023 ("Amendment No. 1") and Amendment No. 2 filed on June 23, 2023 ("Amendment No. 2"), and relates to common stock, par value $1.00 per share ("Common Stock"), of Sylvamo Corporation (the "Issuer"), having its principal executive offices at 6077 Primacy Parkway, Memphis, Tennessee 38119. The Schedule 13D remains in full force and effect, except as specifically amended by this Amendment No. 3. Capitalized terms used but not otherwise defined shall have the respective meanings ascribed to such terms in the Schedule 13D. | ||
| Item 2. | Identity and Background | |
| (a) | Item 2(a) of the Schedule 13D is hereby amended and restated as follows:
(a) This Schedule 13D is filed jointly by:
(i) ACR Group Paper Holdings JR LP, a Delaware limited partnership ("ACR GPH JR"). ACR GPH JR is the direct beneficial owner of 6,312,454 shares of Common Stock of the Issuer;
(ii) ACR Group Paper Holdings JR GP LLC, a Delaware limited liability company ("ACR GPH JR GP"), is the general partner of ACR GPH JR;
(iii) ACR Group Paper Holdings LP, a Delaware limited partnership ("ACR GPH"), is the sole and controlling member of ACR GPH JR GP;
(iv) Atlas Capital GP IV LP, a Delaware limited partnership ("AC GP IV"), is the general partner of ACR GPH;
(v) Atlas Capital Resources GP IV LLC, a Delaware limited liability company ("ACR GP IV"), is the general partner of AC GP IV;
(vi) Atlas GP Global Holdings LLC, a Delaware limited liability company ("AGP GH"), is the manager of ACR GP IV; and
(vii) Andrew M. Bursky and Timothy J. Fazio, each a United States citizen and a manager and Managing Partner of AGP GH, which may be deemed to control ACR GPH JR, ACR GPH JR GP, ACR GPH, AC GP IV and ACR GP IV.
Each of Messrs. Bursky and Fazio, together with ACR GPH JR, ACR GPH JR GP, ACR GPH, AC GP IV, ACR GP IV and AGP GH are sometimes collectively referred to herein as the "Reporting Persons" and each individually as a "Reporting Person."
Each Reporting Person expressly disclaims beneficial ownership with respect to any Common Stock of the Issuer, other than the Common Stock of the Issuer owned directly by such Reporting Person.
Set forth on Exhibit 99.5 hereto are the (i) name, (ii) business address, (iii) present principal occupation or employment and (iv) citizenship of all of the directors and executive officers or persons holding equivalent positions of the Reporting Persons (collectively, the "Scheduled Persons", and each a "Scheduled Person"). | |
| (c) | Item 2(c) of the Schedule 13D is hereby amended and restated as follows:
(c) The principal business of the Reporting Persons is as follows:
(i) ACR GPH makes private equity and related investments in business organizations;
(ii) AC GP IV is the general partner of ACR GPH and certain other funds;
(iii) ACR GP IV is the general partner of AC GP IV;
(iv) AGP GH is the manager of ACR GP IV;
(v) Messrs. Bursky and Fazio are managers and Managing Partners of AGP GH;
(vi) ACR GPH JR and ACR GPH JR GP were formed to effect the transactions described in Items 3 and 6 of Amendment No. 2. | |
| Item 4. | Purpose of Transaction | |
Item 4 of the Schedule 13D is hereby amended and supplemented to include the following:
"On November 5, 2025, in order to terminate the "Cooperation Period" under the Cooperation Agreement by and among certain of the Reporting Persons and the Issuer, the Reporting Persons that are party to the Cooperation Agreement (i) delivered to Karl Meyers and Mark Wilde, each a director of the Issuer, a notice designating in writing that Mr. Meyers and Mr. Wilde resign from the board of directors of the Issuer (each such notice, a "Director Resignation Notice") and notified the Issuer in writing that such Director Resignation Notices were delivered and (ii) delivered notice to the Issuer in writing that the Atlas Group (as defined in the Cooperation Agreement) waives its rights under Section 1(c)(i) of the Cooperation Agreement to recommend a substitute person to replace either Mr. Meyers or Mr. Wilde as directors of the Issuer. The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the Cooperation Agreement, which is attached as Exhibit 99.2 to Amendment No. 1 and is incorporated herein by reference.
Although the Reporting Persons are considering plans or proposals with respect to their investment in the Issuer that could relate to or would result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D, except to the extent described herein, the Reporting Persons have no present plans or proposals that relate to or would result in any such matters.
The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including the Issuer's financial position and strategic direction, actions taken by the Board, price levels of the Common Stock of the Issuer, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of Common Stock of the Issuer or other securities or derivative instruments related thereto or selling some or all of their shares of Common Stock of the Issuer or other securities or derivative instruments, engaging in hedging or similar transactions with respect to the Common Stock of the Issuer and, alone or with others, may engage in communications with directors and officers of the Issuer, other stockholders of the Issuer or other third parties or may take steps to implement a course of action, including, without limitation, engaging advisors, including, without limitation, legal, financial, regulatory, technical and/or industry advisors, to assist in any review. Such discussions and other actions may relate to various alternative courses of action, including, without limitation, those related to an extraordinary corporate transaction (including, but not limited to a merger, reorganization or liquidation) involving the Issuer or any of its subsidiaries; business combinations involving the Issuer or its subsidiaries; a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; material asset purchases; the formation of joint ventures with the Issuer or its subsidiaries or the entry into other material projects; changes in the present business, operations, strategy, future plans or prospects of the Issuer, financial or governance matters; changes to the Board (including, without limitation, Board composition) or management of the Issuer; acting as a participant in debt financings of the Issuer or its subsidiaries; changes to the capitalization, ownership structure, dividend policy, business or corporate structure or governance documents of the Issuer; de-listing or de-registration of the Issuer's securities; the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D or any action similar to those enumerated above." | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Items 5(a) and (b) of the Schedule 13D are hereby amended and restated as follows:
The information contained on the cover pages of this Schedule 13D is incorporated by reference. All percentages of Common Stock outstanding contained herein are based on 40,372,555 shares of Common Stock outstanding as of August 1, 2025, according to the Form 10-Q filed by the Issuer with the SEC on August 8, 2025.
In the aggregate, the Reporting Persons beneficially own, as of the date hereof, 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares.
(i) ACR GPH JR has shared voting and dispositive power over 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares;
(ii) ACR GPH JR GP, by virtue of its status as the general partner of ACR GPH JR, has shared voting and dispositive power over 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares;
(iii) ACR GPH, by virtue of its status as the sole and controlling member of ACR GPH JR GP, has shared voting and dispositive power over 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares;
(iv) AC GP IV, by virtue of its status as the general partner of ACR GPH and certain other funds, has shared voting and dispositive power over 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares;
(v) ACR GP IV, by virtue of its status as the general partner of AC GP IV, has shared voting and dispositive power over 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares;
(vi) AGP GH, by virtue of its status as the manager of ACR GP IV, has shared voting and dispositive power over 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares;
(vii) each of Messrs. Bursky and Fazio, by virtue of his status as a manager and Managing Partner of AGP GH, has shared voting and dispositive power over 6,312,454 shares of Common Stock, representing 15.64% of the outstanding shares.
Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. | |
| (e) | Item 5(e) of the Schedule 13D is hereby amended and restated as follows:
(e) Not applicable. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Item 6 of the Schedule 13D is hereby amended and supplemented with the following:
"Margin Loan Facility
Pursuant to the Loan Agreement, as of the date hereof, ACR GPH JR has borrowed an aggregate of approximately $254.9 million." | ||
| Item 7. | Material to be Filed as Exhibits. | |
99.4 Joint Filing Agreement, dated as of November 6, 2025, by and among the Reporting Persons
99.5 Information Regarding Scheduled Persons | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comments accompanying signature:
(1) Timothy J. Fazio is signing as Managing Partner of Atlas GP Global Holdings LLC, which is the manager of Atlas Capital Resources GP IV LLC, which is the general partner of Atlas Capital GP IV LP, which is the general partner of ACR Group Paper Holdings LP. |
FAQ
What stake in Sylvamo (SLVM) do the reporting persons disclose?
They report beneficial ownership of 6,312,454 shares, representing 15.64% of Sylvamo’s common stock.
What share count was used to calculate the 15.64% for SLVM?
Percentages are based on 40,372,555 shares outstanding as of August 1, 2025, per the issuer’s Form 10‑Q.
What governance action is described regarding Sylvamo’s board?
On November 5, 2025, Director Resignation Notices were delivered designating Karl Meyers and Mark Wilde resign, and the right to recommend substitutes was waived.
Did the filing mention any financing arrangements by the holders?
Yes. ACR Group Paper Holdings JR LP has borrowed approximately $254.9 million under a margin loan facility.
Who are the reporting persons in the Sylvamo 13D/A?
Entities include ACR Group Paper Holdings JR LP and affiliated Atlas/ACR entities, plus individuals Andrew M. Bursky and Timothy J. Fazio.
What voting and dispositive power do they report over SLVM shares?
They report shared voting and dispositive power over 6,312,454 shares.
Do the reporting persons state any specific future plans for SLVM?
They state they may consider various actions regarding strategy, transactions, governance, or securities activity and will review their investment on an ongoing basis.